Minireview Article

Factors Contributing In Incidence And Diagnosis Of Metabolic syndrome: Updated Mini review

Abstract

It has been well-established that obesity is the major contributing factor forthe development of metabolic syndrome (MetS), diabetes, cardiovascular disease and certain types of cancer. According to WHO, 44% increase of diabetes, 23% increase of ischaemic heart disease, and between 7% and 41% increase of certain cancer are due to obesity. The Middle East region is reported to have the highest prevalence of diabetes in adults in the world. In Saudi Arabia, over 35% of the population are obese, and it is estimated that 24% of adult has diabetes including undiagnosed diabetes cases. Obesity and chronic metabolic disease associated obesity impose the heavy financial burden on national healthcare in the Gulf countries as they do in most countries worldwide. Biochemical markers for MetS included changes in trace elements, vitamin D,hormonal (adipokines, leptin, adiponectin, ghrelin), inflammatory mediators (IL-6, TNF-α, IL-10), biochemical markers (Ox-LDL, uric acid) and prothrombic factors (PAI-1).Plasminogen Activator Inhibitor-1 (PAI-1) is the primary of four serine peptidase inhibitors that functions to modulate extracellular matrix remodeling and fibrinolysis. The link between PAI-1 and MetS has been established. This review screening major factors and the association between PAI-1, trace elemnts, vitamin D, obesity hormone and expression of obesity genes for early prediction of MetS for control and management to prevent late complications.

Keywords: Metabolic syndrome-insulin-plasminogen factor-trace elements

Background

In Gulf countries, it was reported that non-communicable diseases (NCDs) as obesity will cost $68 billion in 2030. The medical healthcare expenditures that are increased ten times higher ($3,686 vs. $380) [1]. These reports underline the urgent needs for a strategy to reduce the occurrence of these diseases and health care burden derived from it not only in the Middle East but also globally [2].The obesity rate has increased dramatically worldwide and emerged as a major global challenge. Obesity is a serious health concern because it is a risk factor for other diseases including diabetes, coronary heart disease, hypertension and certain types of cancer. In the Middle East, the prevalence of obesity has arisen as a substantial issue with 35% of obese rate in adult, and in accordance, the highest diabetes rate in the world [3]. A recent report has shown that 35.2% of Saudi Arabian population is obese, the second highest in the world. Current therapeutic approaches to treat obesity using drugs are unsatisfactory due to numerous side effects [4].

Diet-induced metabolic syndromes are widely spread nutritional disorders around the world and have arisen as a growing global challenge. Among them, obesity is a significant risk factor for other diseases including diabetes, coronary heart disease, hypertension, atherosclerosis and certain forms of cancer. Obesity is defined by a body mass index ≥ 30 according to the World Health Organization (WHO) [5]. Obesity arises from energy imbalance due to excessive energy intake from food consumption and insufficient energy expenditure which includes basal metabolism, physical activity and adaptive thermogenesis. In the Middle East, the prevalence of obesity has increased dramatically and become a serious health concern in the recent decades [6]. There is a notable increase in the incidence of obesity in Arabic-speaking countries with a prevalence of 2 to 55% in females and 1 to 30% in males. Increased consumption of fats, sugars, and carbohydrates in these countries is associated with change of dietary habits by Westernization, which can increase the risk for obesity. It is now known that obesity is the major cause of metabolic diseases such as type 2 diabetes and cardiovascular diseases (CVDs), yet mechanistic understanding of this pathology and current therapeutics are unsatisfactory [7].

The identificatiobn of genes that increase incidence for development of obesity hasbecome intersted. One of these genes is the GNB. Its name derived from the G-protein (GNB3) gene, which formed from 12 exons, present on chromosome 12p13 and produce β3 unit of G proteins. The polymorphism of this gene leads to a truncated splice variant . The *GNB3* 825**T** allele product has been associated with obesity, hypertension, and atherosclerosis [8].

The burgeoning rate of obesity is not only indicated in adult population, but also in children and adolescents [9]. This high prevalence of obesity has paralleled the rise of diabetes and hypertension . Poor eating habits and physical inactivity due to their greasy and high calorie diet and sedentary lifestyle, respectively, are known to be the major contributors of obesity in the Middle Eastern population .The changes in diet of the Arab World includes increased calorie intake and substitution of the traditional diet with refined and processed foods and diets high in fat and salt. Recent studies have reported that natural compounds found in cruciferous vegetables such as broccoli, cabbage and radish have numerous beneficial effects on various diseases such as cancer, cardiovascular disease, and inflammation [10]. Adipogenesis and lipogenesis through cell cycle arrest and activation of AMP-activated protein kinase (AMPK) [11], but also promoting lipolysis mediated by activation of hormone-sensitive lipase (HSL), a lipase in adipocyte . Moreover, the exact mechanism of action of them in various organs which are closely related to obesity and insulin resistance have not been clearly understood. Therefore, it is important to prevent overweight or obesity to reduce the risk factor threatening our healthy lives. Regardless of which criteria are used, the primary concern is early detection of potential CVD complications and early intervention [12].The prevalence of MetS in Saudi subjects was reported by Al-Nozha et al. to be 39.3% **[13].**
The aim of current survey for monitoring major factors that contribute for metabolic syndrome like plasma vitamin B_{12} , trace elements, prothrombic factors (PAI-1), lipid profile, hormonal changes (insulin, leptin and Ghrelin) as a predictive biomarkers for metabolic syndrome.

Prevalence of MetS estimates by coagulation factors

Plasminogen Activator Inhibitor-1 (PAI-1) is a serine protease inhibitor that play a role in modulation of fibrinolysis. Its level is regarded as a index of an abnormal fibrinolysis and thrombosis. The correlation between PAI-1 and MetS was reported to be elevated and strongly association such MetS [14-17]. In efforts to treat obesity and its related metabolic diseases, numerous synthetic drugs and therapeutic approaches have been develop [18]. However, currently there are no effective drugs for obesity without side effects [19]. For examples, several drugs such as sibutramine andreductil are withdrawn from the pharmaceutical market due to their severe side effects [13]. Moreover, even though many synthetic drugs undergo developmental process, they failed during clinical phase trials due to their ineffectiveness or side effects.

Prevalence of MetS estimates by age

The risk of MetS is correlated to age, It was found that, less than 10% of subjects at age 20s and 40 % at age 60s were affected. On the other hand, other reports revealed that in school children other factors may contribute as fast foods and soft drinks. There was correlation between childhood MetS and adult incidence of CHD **[20].** It has been suggested that SES influences nutrition and sedentary habits, which are highly related to MetS components**.** Lower levels of education are associated with higher prevalence of MetS **[21].**

Environmental
- Physical inactivity
- Smoking
- Energy dense food
- Stress

Genetics
- Thrifty genotype
- Thrifty phenotype

Positive energy balance

Adipose tissue hyperplasia and hypertrophy

Altered FFA metabolism

Altered release of adipokines

↑ Leptin
↑ AT II
↑ Aldosterone

↑ Factor VII
↑ Factor V
↑ PAI-I

↑ Portal FFA

Insulin resistance hyperinsulinemia

Activate RAAS and SNS

Oxidative stress endothelial dysfunction

↑ Lipoprotein synthesis
↑ Gluconeogenesis

Impairs β-cell function of pancreas

↑ Sodium reabsorption vasoconstriction

Proinflammatory state prothrombotic state

Dyslipidemia

Hyperglycemia overt T2DM

Hypertension

Hypercoagulable state

Metabolic syndrome

Figure (1):Factors associated with MetS. (FFA: free fatty acid, ATII: angiotensin II, PAI-1: plasminogen activator inhibitor-1, RAAS: renin angiotensin aldosterone system, SNS: sympathetic nervous system [21].

Prevalence of MetS caused by oxidative stress

Another factor contributing to the development of the MetS is excessive ROS formation which can alter the mitochondrial function and endoplasmic reticulum which again will lead to defective insulin secretion and DMT2. Increased oxidative stress in accumulated

117 fat, via increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and

118 decreased antioxidant enzymes [15].

119

120   Figure (2): Impact of ROS production in accumulated fat contributes to
121 metabolic syndrome [15].

122

123

124

Prevalence of MetS affected by insulin action

Insulin resistance with hyperinsulinemia seems to be a central factor in the pathogenesis of the MetS. An insulin-resistant state interferes with the hormonal actions taking place in the liver. Insulin produced in the β-cells of the pancreas travels quickly to the liver via the portal vein, and in the presence of the MetS, insulin has a selective dysfunction so that it does not diminish the hepatic glucose output, but rather increases it, and still, like in the normal state, increases the de novo lipogenesis, thereby releasing triglycerides to the circulation, causing dyslipidemia [22]. Further, insulin resistance causes increased renal sodium reabsorption and stimulate the sympathetic nervous system which can result in hypertension [23].

Prevalence of MetS by biochemical markers

Metabolomics is a new research trend used to measure different metabolites for screening diagnosis and prognosis of some diseases. Some vitamins as A, D were implicated in MetS. The obesity is considered as a type of inflammation due to oxidative stress and elevated free radicals. This is indicated by release of inflammatory mediators as(IL-6, TNF-α, IL-10). Trace elements are important for activation of some enzymes, synthetic pathway, and biomolecules. Their levels are changes and taken as markers for different diseases. Some of it were implicated in MetS as Zn, Cu, Fe and Se. In addition, hormonal changes as(adipokines, leptin, adiponectin, ghrelin) and biochemical markers (Ox-LDL, PON-1, uric acid) are important biochemical markers for MetS.

Prevalence of MetS by trace elements

Trace elements has an important role in metabolism, growth, immunological, and neurological functions Copper (Cu), one of these elements, is mainly found in shellfish, organ meats, nuts, seeds, vegetables, and grains [24]. Throughout the years it has been shown that Cu abnormalities are linked to CVD [25] and cancer [20]. In fact, its deficiency may lead to arterial diseases and myocardial disease, besides pigmentation loss and neurological effects. Cu has an important role in the defense against free radical damage as an antioxidant [26]. Previous study found that Cu levels were significantly higher in subjects with MetS than in subjects without MetS, however, they did not analyze these values according to weight, since they also found that serum Cu levels were significantly higher in obese than in normal subjects and it is known that increasing weight increases the risk for developing MetS. The causal relationship between obesity and concentration of iron in the teenagers was already established [27].Further to that, a

159 causal association between low blood Fe concentrations and adiposity in people has been
160 noted [28].

Conclusions

Metabolic syndrome knowledge is essential for diagnosis and management for development of protocol for fast management for MetS. This will help to prevent and control risk diabetes, hypertension, Cardiovascular diseases and carcinogenic.

References

1. Song Q-B, Zhao Y, Liu Y-Q, Zhang J, Xin S-J, Dong G-H. Sex difference in the prevalence of metabolic syndrome and cardiovascular-related risk factors in urban adults from 33 communities of China: The CHPSNE study. Diab Vasc Dis Res. 2015; 12(3): 189-98.

2. Ajayi EA, Ajayi OA, Adeoti OA. Metabolic syndrome: prevalence and association with electrocardiographic abnormalities in Nigerian hypertensive patients. Metab Syndr Relat Disord. 2014; 12(8): 437-42.

3.Turi BC, Codogno JS, Fernandes RA, Monteiro HL, Turi BC, Codogno JS, et al. Low levels of physical activity and metabolic syndrome: cross-sectional study in the Brazilian public health system. Cienc saude coletiva. 2016; 21(4): 1043-50.

4. Granfeldt G, Ibarra J, Mosso C, Munoz S, Carrillo KS, Zapata D. Capacidad predictiva de los indices antropometricos en la deteccion de Sindrome Metabolico en adultos chilenos. Arch Latinoam Nutr. 2015; 65(3): 152-7.

5. Mora G, Salguedo G, Ruiz M, Ramos E, Alario A, Fortich A, et al. Concordancia entre cinco definiciones de sindrome metabolico. Cartagena, Colombia. Rev Esp Salud Publica. 2012; 86(3): 301-11.

6. Bahrani R, Chan YM, Khor GL, Rahman HA, Esmailzadeh A, Wong TW. The relationship between metabolic syndrome and its components with socio-economic status among adolescents in Shiraz, southern Iran. Southeast Asian J Trop Med Public Health. 2016; 47(2): 263-76.

7. Rerksuppaphol S, Rerksuppaphol L. Metabolic Syndrome in Obese Thai Children: Defined Using Modified [The National Cholesterol Education Program/Adult Treatment Panel III]Criteria. J Med Assoc Thai. 2015; 98(Suppl 10): S88-95.

8. Philco P, Seron P, Munoz S, Navia P, Lanas F. Factores asociados a sindrome metabolico en la comuna de Temuco, Chile. Rev Med Chil. 2012; 140(3): 334-9.

9. Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care. 2010; 33(11): 2457-61.

10. Sheu WH-H, Chuang S-Y, Lee W-J, Tsai S-T, Chou P, Chen C-H. Predictors of incident diabetes, metabolic syndrome in middleaged adults: a 10-year follow-up study from Kinmen, Taiwan. Diabetes Res Clin Pract. 2006; 74(2): 162-8.

11. Alnory A, Gad H, Hegazy G, Shaker O. The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in Egyptian women. Turk J Med Sci. 2016;46(5): 1335-40.

12. Hotta K, Kitamoto T, Kitamoto A, Mizusawa S, Matsuo T, Nakata Y, et al. Association of variations in the FTO, SCG3 and MTMR9 genes with metabolic syndrome in a Japanese population. J Hum Genet. 2011; 56(9): 647-51.

203 13. Zhao X, Xi B, Shen Y, Wu L, Hou D, Cheng H, et al. An obesity genetic risk score is
204 associated with metabolic syndrome in Chinese children. Gene. 2014; 535(2): 299-302.
205 14. Mazidi M, Rezaie P, Kengne AP, Mobarhan MG, Ferns GA. Gut microbiome and
206 metabolic syndrome. Diabetes Metab Syndr. 2016; 10(2 Suppl 1): S150-7.
207 15. Hunter I, Soler A, Joseph G, Hutcheson B, Bradford C, Zhang FF, et al.
208 Cardiovascular function in male and female JCR:LA-cp rats: effect of high-fat/high-
209 sucrose diet. Am J Physiol Heart Circ Physiol. 2017; 312(4): H742-51.
210 16. Nettleton JA, Lutsey PL, Wang Y, Lima JA, Michos ED, Jacobs DR. Diet soda intake
211 and risk of incident metabolic syndrome and type 2 diabetes in the Multi-Ethnic Study of
212 Atherosclerosis (MESA). Diabetes Care. 2009; 32(4): 688-94.
213 17.Haby MM et al. A new approach to assessing the health benefit from obesity
214 interventions in children and adolescents: the assessing cost-effectiveness in obesity
215 project. International Journal of Obesity (London), 2006, 30(10):1463–75.
216 18.Carter R et al. Assessing Cost-Effectiveness in Obesity (ACE-Obesity): an overview
217 of the ACE approach, economic methods and cost results. BMC Public Health, 2009,
218 9:419.
219 19.Tackling Obesities: Future Choices – Project report. Foresight, London, Government
220 Office for Science, 2007. Available at: http://www.bis.gov.uk/foresight/our-
221 work/projects/published-projects/tackling-obesities [accessed 30 November 2011].
222 20.Robertson A et al., eds. Food and health in Europe: a new basis for action (WHO
223 regional publications. European series, No. 96). Copenhagen, World Health
224 Organization, 2004.65 Best options for promoting healthy weight and preventing weight
225 gain in NSW. Sydney, New South Wales Department of Health, 2005.
226 21.Griffiths J, Maggs H, George E. 'Stakeholder Involvement': Background paper
227 prepared for the WHO/WEF joint event on Preventing Noncommunicable Diseases in the
228 Workplace (Dalian/China, September 2007). Geneva, World Health Organization, 2008.
229 Milio N. Nutrition and health: patterns and policy perspectives in food-rich countries.
230 Social Science & Medicine, 1989, 29(3):413–23.
231 22.Swinburn BA. Obesity prevention: the role of policies, laws and
232 regulations.(Commentary). Australia & New Zealand Health Policy, 2008, 5:12.
233 23.Snowdon W et al. Prioritizing policy interventions to improve diets? Will it work, can
234 it happen, will it do harm? Health Promotion International, 2010, 25(1):123–33.
235 24.Keating CL et al. Cost-effectiveness of surgically induced weight loss for the
236 management of type 2 diabetes: modeled lifetime analysis. Diabetes Care, 2009,
237 32(4):567–74.
238 25.Picot J et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss)
239 surgery for obesity: a systematic review and economic evaluation. Health Technology
240 Assessment, 2009, 13(41):1–190, 215–357, iii-iv.
241